ARCHIVED - References

 

  1. Demers B, Simor AE, Vellend H et al. Severe invasive group A streptococcal infections in Ontario, Canada: 1987-1991. Clin Infect Dis 1993;16:792-800.
  2. Efstratiou A. Group A streptococci in the 1990s. J Antimicrob Chemother 2000;45:3-12.
  3. Eriksson KG, Andersson J, Holm SE et al. Epidemiological and clinical aspects of invasive group A streptococcal infections and the streptococcal toxic shock syndrome. Clin Infect Dis 1998;27:1428-36.
  4. Stevens DL. Invasive group A streptococcal infections: The past, present and future. Pediatr Infect Dis J 1994;13:561-6.
  5. Hoge CW, Schwartz B, Talkington DF et al. The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome. JAMA 1993;269:384-9.
  6. Schwartz B, Facklam RR, Breiman RF. Changing epidemiology of group A streptococcal infection in the USA. Lancet 1990;336:1167-71.
  7. Bisno AL, Stevens DL. Streptococcus pyogenes (including streptococcal toxic shock syndrome and necrotizing fasciitis). In:Mandell GL,Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 5th ed. Philadelphia: Churchill Livingstone, 2000:2101-17.
  8. Health Canada. Notifiable diseases annual summary: 2001. CCDR 2004;30S3:92-4.
  9. International Circumpolar Surveillance (ICS) summary report: Year 2000 data. Anchorage: International Circumpolar Surveillance, 2002.
  10. International Circumpolar Surveillance (ICS) summary report: Year 2001 data. Anchorage: International Circumpolar Surveillance, 2003.
  11. International Circumpolar Surveillance (ICS) summary report: Year 2002 data. Anchorage: International Circumpolar Surveillance, 2005.
  12. International Circumpolar Surveillance (ICS) preliminary summary report: Year 2003 data. Anchorage: International Circumpolar Surveillance, 2005.
  13. Tyrrell GJ, Lovgren M, Forwick B et al. M types of group A Streptococcal isolates submitted to the National Centre for Streptococcus (Canada) from 1993 to 1999. J Clin Microbiol 2002;40:4466-71.
  14. Annual report for April 1, 2002 to March 31, 2003. Edmonton: National Centre for Streptococcus, 2003.
  15. Annual report for April 1, 2003 to March 31, 2004. Edmonton: National Centre for Streptococcus, 2004.
  16. Annual report for April 1, 2004 to March 31, 2005. Edmonton: National Centre for Streptococcus, 2005.
  17. Davies HD, McGeer A, Schwartz B et al. Invasive group A streptococcal infections in Ontario, Canada. N Engl J Med 1996;335:547-54.
  18. Sharkawy A, Low DE, Saginur R et al. Severe group A streptococcal soft-tissue infections in Ontario: 1992-1996. Clin Infect Dis 2002;34:454-60.
  19. Muller MP, Low DE, Green KA et al. Clinical and epidemiologic features of group A streptococcal pneumonia in Ontario, Canada. Arch Intern Med 2003;163:467-72.
  20. Tyrrell GJ, Lovgren M, Kress B et al. Invasive group A streptococcal disease in Alberta, Canada (2000 to 2002). J Clin Microbiol 2005;43:1678-83.
  21. Health Canada. Case definitions for diseases under national surveillance. CCDR 2000;26S3:1-134.
  22. Robinson KA, Rothrock G, Phan Q et al. Risk for severe group A streptococcal disease among patients' household contacts. Emerg Infect Dis 2003;9:443-7.
  23. Schwartz B, Elliott JA, Butler JC et al. Clusters of invasive group A streptococcal infections in family, hospital, and nursing home settings. Clin Infect Dis 1992;15:277-84.
  24. Davies HD. Invasive group A streptococcal infections: Canadian Pediatric Society Position Statement. Pediatr Child Health 1999;4:73-5. URL: <http://www.cps.ca/english/statements/ ID/id98-05.htm>.
  25. American Academy of Pediatrics. Red book: 2003 report of the Committee on Infectious Diseases, 26th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2003.
  26. Guidelines for the treatment of necrotizing fasciitis (NF) and Streptococcal toxic shock syndrome (STSS). Toronto: Ontario Group A Streptococcal Study, 1998. URL: <http://microbiology.mtsinai.on.ca/protocols/pd f/k5a.pdf>.
  27. Prevention of Invasive Group A Streptococcal Infections Working Group. Prevention of invasive group A streptococcal disease among household contacts of case patients and among postpartum and postsurgical patients: Recommendations from the Centers for Disease Control and Prevention. Clin Infect Dis 2002;35:950-9.
  28. Health Protection Agency, Group A Streptococcus Working Group. Interim UK guidelines for management of close community contacts of invasive group A streptococcal disease. Commun Dis Public Health 2004;7:354-61.
  29. Valenzuela TD, Hooton TM, Kaplan EL et al. Transmission of toxic strep syndrome from an infected child to a firefighter during CPR. Annals Emerg Med 1991;20:90-2.
  30. Bohlen LM, Muhlemann K, Dubuis O et al. Outbreak among drug users caused by a clonal strain of group A streptococcus. Emerg Infect Dis 2000;6:175-9.
  31. Lechot P, Schaad HJ, Graf S et al. Group A streptococcus clones causing reported epidemics and endemic disease in intravenous drug users. Scand J Infect Dis 2001;33:41-6.
  32. Brunner S, Fleisch F, Ruef C et al. Automated ribotyping and pulsed-field gel electrophoresis reveal a cluster of group A streptococci in intravenous drug abusers. Infection 2000;28:314-7.
  33. 33. Smolyakov R, Riesenberg K, Schlaeffer F et al. Streptococcal septic arthritis and necrotizing fasciitis in an intravenous drug user couple sharing needles. Isr Med Assoc J 2002;4:302-3.
  34. Weiss K, Laverdiere M, Lovgren M et al. Group A Streptococcus carriage among close contacts of patients with invasive infections. Am J Epidemiol 1999;149:863-8.
  35. Smith A, Li A, Tolomeo O et al. Mass antibiotic treatment for group A streptococcus outbreaks in two long-term care facilities. Emerg Infect Dis 2003;9:1260-5.
  36. Hansen JL, Paulissen JP, Larson AL et al. Nursing home outbreaks of invasive group A streptococcal infections - Illinois, Kansas, North Carolina and Texas. MMWR 1990;39:577-9.
  37. Barry MA, Matthew K, Tormey P et al. Outbreak of invasive group A streptococcus associated with varicella in a childcare center -Boston, Massachusetts, 1997. MMWR 2004;46:944-8.
  38. Falck G, Kjellander J. Outbreak of group A streptococcal infection in a day-care center. Pediatr Infect Dis J 1992;11:914-9.
  39. Engelgau MM, Woernle CH, Schwartz B et al. Invasive group A streptococcus carriage in a child care centre after a fatal case. Arch Dis Child 1994;71:318-22.
  40. Husain E, Bigham M, Davies D et al. Invasive group A streptococcus in two siblings: A case for antibiotic prophylaxis of close contacts. CCDR 2001;27:141-6.
  41. Ruben FL, Norden CW, Heisler B et al. An outbreak of Streptococcus pyogenes infections in a nursing home. AnnInternMed 1984;101:494-6.
  42. Harkness GA, Bentley DW, Mottley M et al. Streptococcus pyogenes outbreak in a long-term care facility. Am J Infect Control 1992;20:142-8.
  43. Auerbach SB, Schwartz B, Williams D et al. Outbreak of invasive group A streptococcal infections in a nursing home. Lessons on prevention and control. Arch Intern Med 1992;152:1017-22.
  44. Reid RI, Briggs RS, Seal DV et al. Virulent Streptococcus pyogenes: Outbreak and spread within a geriatric unit. J Infect 1983;6:219-25.
  45. Barnham M, Hunter S, Hanratty B et al. Invasive M-type 3 Streptococcus pyogenes affecting a family and a residential home. Commun Dis Public Health 2001;4:64-7.
  46. Greene CM, Van Beneden CA, Javadi M et al. Cluster of deaths from group A streptococcus in a long-term care facility - Georgia, 2001. Am J Infect Control 2005;33:108-13.
  47. Brogan TV, Nizet V, Waldhausen JH et al. Group A streptococcal necrotizing fasciitis complicating primary varicella: A series of fourteen patients. Pediatr Infect Dis J 1995;14:588-94.
  48. Wilson GJ, Talkington DF, Gruber W et al. Group A streptococcal necrotizing fasciitis following varicella in children: Case reports and review. Clin Infect Dis 1995;20:1333-8.
  49. Galanis E, Skotniski E, Panaro L et al. Investigation of a varicella outbreak complicated by group A streptococcus in First Nations Communities, Sioux Lookout Zone, Ontario. CCDR 2002;28:157-63.
  50. Laupland KB, Davies HD, Low DE et al. Invasive group A streptococcal disease in children and association with varicella-zoster virus infection. Pediatrics 2000;105:e60-e67.
  51. Hollm-Delgado M-G, Allard R, Pillon PA. Invasive group A streptococcal infections, clinical manifestations and their predictors, Montreal, 1995-2001. Emerg Infect Dis 2005;11:77-82.
  52. Tyrell GJ, Lovgren M, Kress B et al. Varicella-associated invasive group A streptococcal disease in Alberta, Canada - 2000-2002. Clin Infect Dis 2005;40:1055-7.
  53. National Advisory Committee on Immunization (NACI). Update on varicella. CCDR 2004;30(ACS-1):1-27.
  54. Peterson CL, Vugia DJ, Meyers HB et al. Risk factors for invasive group A streptococcal infections in children with varicella: A case-control study. Pediatr Infect Dis J 1996;15:151-6.
  55. Well being: A guide to promote the physical health, safety and emotional well-being of children in child care centres and family day care homes. Ottawa: Canadian Pediatric Society, 1996.
  56. Shulman ST, Gerber MA. So what's wrong with penicillin for strep throat? Pediatrics 2004;113:1816-9.
  57. Casey JR, Pichichero ME. Meta-analysis of cephalosporins versus penicillin for treatment of group A streptococcal tonsillopharyngitis in adults. Clin Infect Dis 2004;38:1526-34.
  58. Gerber MA, Tanz RR, Kabat W et al. Potential mechanisms for failure to eradicate group A streptococci from the pharynx. Pediatrics 1999;104:911-7.
  59. Bisno AL. Are cephalosporins superior to penicillin for treatment of acute streptococcal pharyngitis? Clin Infect Dis 2004;38:1535-7.
  60. Casey JR, Pichichero ME. Meta-analysis of cephalosporins versus penicillin for treatment of group A streptococcal tonsillopharyngitis in children. Pediatrics 2004;113:866-82.
  61. Bisno AL, Gerber MA, Gwaltney JM et al. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Clin Infect Dis 2002;35:113-25.
  62. Canadian Pediatric Society. Treatment of group A streptococcal pharyngitis. Can J Infect Dis 1997;8:17-8.
  63. Syrogiannopoulos GA, Bozdogan B, Grivea IN et al. Two dosages of clarithromycin for five days, amoxicillin/clavulanate for five days or penicillin V for ten days in acute group A streptococcal tonsillopharyngitis. Pediatr Infect Dis J 2004;23:857-65.
  64. Kafetzis DA, Liapi G, Tsolia M et al. Failure to eradicate group A beta-haemolytic streptococci (GABHS) from the upper respiratory tract after antibiotic treatment. Int J Antimicrob Agents 2004;23:67-71.
  65. Takker U, Dzyublyk O, Busman T et al. Comparison of 5 days of extended-release clarithromycin versus 10 days of penicillin V for the treatment of streptococcal pharyngitis/ tonsillitis: Results of a multicenter, double-blind, randomized study in adolescent and adult patients. Curr Med Res Opin 2003;19:421-9.
  66. Portier H, Filipecki J, Weber P et al. Five day clarithromycin modified release versus 10 day penicillin V for group A streptococcal pharyngitis: A multi-centre, open-label, randomized study. J Antimicrob Chemother 2002;49:337-44.
  67. McCarty J, Hedrick JA, Gooch WM. Clarithromycin suspension vs penicillin V suspension in children with streptococcal pharyngitis. Adv Ther 2000;17:14-26.
  68. Tanz RR, Poncher JR, Corydon KE et al. Clindamycin treatment of chronic pharyngeal carriage of group A streptococci. JPediatr 1991;119:123-8.
  69. Gallegos B, Rios A, Espidel A et al. A double-blind, multicenter comparative study of two regimens of clindamycin hydrochloride in the treatment of patients with acute streptococcal tonsillitis/pharyngitis. Clin Ther 1995;17:613-21.
  70. Schaad UB. Acute streptococcal tonsillopharyngitis: a review of clinical efficacy and bacteriological eradication. JInt MedRes 2004;32:1-13.
  71. Kaplan EL, Johnson DR. Unexplained reduced microbiological efficacy of intramuscular benzathine penicillin G and of oral penicillin V in eradication of group A streptococci from children with acute pharyngitis. Pediatrics 2001;108:1180-6.
  72. 72. Kuhn SM, Preiksaitis J, Tyrell GJ et al. Evaluation of potential factors contributing to microbiological treatment failure in Streptococcus pyogenes pharyngitis. Can J Infect Dis 2001;12:33-9.
  73. Kaplan EL, Gastanaduy AS, Huwe BB. The role of the carrier in treatment failures after antibiotic for group A streptococci in the upper respiratory tract. J Lab Clin Med 1981;98:326-35.
  74. Sela S, Neeman R, Keller N et al. Relationship between asymptomatic carriage of Streptococcus pyogenes and the ability of the strains to adhere to and be internalised by cultured epithelial cells. J Med Microbiol 2000;49:499-502.
  75. Cohen R. Defining the optimum treatment regimen for azithromycin in acute tonsillopharyngitis. Pediatr Infect Dis J 2004;23:S129-S134.
  76. Vanderkooi OG, Low DE, Green K et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005;40:1288-97.
  77. Kotloff KL, Corretti M, Palmer K et al. Safety and immunogenicity of a recombinant multivalent group A streptococcal vaccine in healthy adults: Phase 1 trial. JAMA 2004;292:709-15.
  78. McNeil SA, Halperin SA, Langley JM et al. Safety and immunogenicity of 26-valent group A Streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 2005;41:1114-22.
  79. ID Biomedical announces positive results from phase II clinical trial of Streptavax vaccine. ID Biomedical Corporation, press release, August 10, 2004.
Report a problem or mistake on this page
Please select all that apply:

Privacy statement

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: